Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490658 · ClinicalTrials.gov registry record · Phase 1
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
NCT01490658: Completed Phase 1 study, sponsored by Novo Nordisk A/S.
NCT01490658 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 93 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01490658, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to compare repaglinide and metformin as co-administered tablets and as a combination tablet.
Interventions
- DRUG metformin
- DRUG repaglinide
- DRUG repaglinide and metformin combination tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2006-06 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
What the finished NCT01490658 record still lists
NCT01490658 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% higher).
The record links to 0 conditions, and to 3 interventions - of which metformin is the first listed.
NCT01490658 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01490658 about?
NCT01490658 is a clinical study titled "Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers". This trial is conducted in the United States of America (USA). The aim of this trial is to compare repaglinide and metformin as co-administered tablets and as a combination tablet.
What is the current status of trial NCT01490658?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2006-06. Estimated completion is 2006-08.
What interventions are being tested in trial NCT01490658?
The interventions under investigation include: metformin (DRUG), repaglinide (DRUG), repaglinide and metformin combination tablet (DRUG).
Who is sponsoring clinical trial NCT01490658?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01490658's enrollment target sits among peer trials
93 624th of 2000 higher than 1,376 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia